#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rogers et al.

**Application No.** 10/533,477

Filed: April 29, 2005 Confirmation No. 4053

For: MULTIPLE COMPONENT FOOD

PRODUCT USEFUL FOR DELIVERING FILED VIA EFS ON JUNE 14, 2007

GLUCOSAMINE AND/OR N-ACETYL-D-

**GLUCOSAMINE** 

Examiner: Shengjun Wang

Art Unit: 1617

Attorney Reference No. 6682-66959-02

# INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 C.F.R. § 1.97(b)(3)

## SUBMITTED VIA ELECTRONIC FILING SYSTEM UNITED STATES PATENT AND TRADEMARK OFFICE

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") before the mailing date of a first Office action on the merits. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 595-5300 Facsimile: (503) 595-5301 Sheree Lynn Rybak, Ph.D

Registration No. 47,913

cl P dm	06/14/07	6682 66050 02	710226	CGL02/0396HS02
SLR.um	00/14/07	0082-00939-02	/ 1 (/ ) ) ()	- CG 07/0396UND

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	6682-66959-02
Application Number	10/533,477
Filing Date	April 29, 2005
First Named Inventor	Rogers
Art Unit	1617
Examiner Name	Shengjun Wang

### **U.S. PATENT DOCUMENTS**

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication	n Date Name o	f Applicant or Patentee
		FO	REIGN PATENT I		
Examiner's		Country	Number	Publication	Name of

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO	WO 01/01992 A1	01/11/2001	SCA LOHNHERSTELLUNGS AG and PHARMA BASE S.A.
Examiner's	Cite No.		OTHER I	OCUMENTS	

(optional)	OTHER DOCUMENTS
:	

<u> </u>	
EXAMINER	DATE
SIGNATURE:	CONSIDERED:

<sup>\*</sup> Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.